According to a new study published by the Journal of Pain Research, THC/CBD can have “remarkable analgesic capabilities” in the treatment of chronic refractory pain caused by failed back surgery syndrome.
“This study aimed to evaluate pain and its symptoms in patients with failed back surgery syndrome (FBSS) refractory to other therapies, treated with a combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in association with spinal cord stimulation (SCS)”, states the study’s abstract. “Outpatients referred at Pain Unit of San Vincenzo Hospital in Taormina (Italy), between September 2014 and January 2016”, were evaluated.
For the study, eleven FBSS patients diagnosed with neuropathic pain, and suffering from moderate to severe chronic refractory pain and undergoing treatment with SCS and a combination of THC/CBD for 12 consecutive months, completed the Douleur Neuropathique 4 questionnaire.
“All the included patients discontinued previous unsuccessful therapy at least 2 months before the beginning of the cannabinoid therapy, with the exception of the SCS that was continued. Patients received a fixed dosage of cannabinoid agonists (THC/CBD) that could be increased subjective to pain control response.” A Brief Pain Inventory questionnaire “was administered to measure pain and its interference with characteristic dimensions of feelings and functions”, and the “duration of treatment with SCS and THC/CBD combination was 12 months.”
Researchers found that “Effective pain management as compared to baseline result was achieved in all the cases studied. The positive effect of cannabinoid agonists on refractory pain was maintained during the entire duration of treatment with minimal dosage titration. Pain perception, evaluated through numeric rating scale, decreased from a baseline mean value of 8.18±1.07-4.72±0.9 by the end of the study duration (12 months) (P<0.001).”
The study concludes by stating that “The results indicate that cannabinoid agonists (THC/CBD) can have remarkable analgesic capabilities, as adjuvant of SCS, for the treatment of chronic refractory pain of FBSS patients.”
For the full study, click here.